These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 23242669)

  • 21. A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain.
    Gómez-Gerique JA; Casciano R; Stern L; Rejas J
    Eur J Health Econ; 2004 Oct; 5(3):278-84. PubMed ID: 15714350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparative economic analysis of simvastatin versus atorvastatin: results of the Surrogate Marker Cost-Efficacy (SMaC) study.
    Arikian S
    Clin Ther; 2000 Apr; 22(4):494-6. PubMed ID: 10823368
    [No Abstract]   [Full Text] [Related]  

  • 23. [Cost-effectiveness of atorvastatin in the early treatment of acute coronary syndromes in Germany based on the MIRACL study].
    Lange AP; Szucs TD
    Med Klin (Munich); 2004 Sep; 99(9):500-5. PubMed ID: 15372179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Has cost inhibited the uptake of more potent statins in England?
    Chapman SR; Fitzpatrick RW; Aladul MI
    Pharmacoepidemiol Drug Saf; 2017 Aug; 26(8):984-991. PubMed ID: 28612964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Moving from A to Z: successful implementation of a statin switch program by a large physician group.
    Sy FZ; Choe HM; Kennedy DM; Standiford CJ; Parsons DM; Bruhnsen KD; Stevenson JG; Bernstein SJ
    Am J Manag Care; 2009 Apr; 15(4):233-40. PubMed ID: 19355796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cost effectiveness of atorvastatin for prevention of coronary disease--an analysis of the ASCOT study. Re: the article from DMW 25/26 2004].
    Traut V
    Dtsch Med Wochenschr; 2004 Sep; 129(37):1944. PubMed ID: 15372377
    [No Abstract]   [Full Text] [Related]  

  • 27. A pharmacoeconomic evaluation of aggressive cholesterol lowering in Sweden.
    Olsson A; Casciano R; Stern L; Svangren P
    Int J Cardiol; 2004 Jul; 96(1):51-7. PubMed ID: 15203261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population.
    Simpson RJ; Signorovitch J; Birnbaum H; Ivanova J; Connolly C; Kidolezi Y; Kuznik A
    Mayo Clin Proc; 2009 Dec; 84(12):1065-72. PubMed ID: 19955243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?
    Ara R; Pandor A; Stevens J; Rafia R; Ward SE; Rees A; Durrington PN; Reynolds TM; Wierzbicki AS; Stevenson M
    Eur J Prev Cardiol; 2012 Jun; 19(3):474-83. PubMed ID: 21460076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What price atorvastatin?
    Drug Ther Bull; 2012 Jul; 50(7):73. PubMed ID: 22764068
    [No Abstract]   [Full Text] [Related]  

  • 31. [Cost-effectiveness of atorvastatin for the prevention of coronary disease. An analysis of the ASCOT study].
    Szucs TD; Klose G; Düsing R
    Dtsch Med Wochenschr; 2004 Jun; 129(25-26):1420-4. PubMed ID: 15213873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland.
    Bennie M; Godman B; Bishop I; Campbell S
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):125-30. PubMed ID: 22280202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trends in Use and Expenditures for Brand-name Statins After Introduction of Generic Statins in the US, 2002-2018.
    Lin SY; Baumann K; Zhou C; Zhou W; Cuellar AE; Xue H
    JAMA Netw Open; 2021 Nov; 4(11):e2135371. PubMed ID: 34807258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men.
    Peura P; Martikainen J; Soini E; Hallinen T; Niskanen L
    Curr Med Res Opin; 2008 Jun; 24(6):1823-32. PubMed ID: 18485270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of out-of-pocket expenses on discontinuation of statin therapy: a cohort study in Finland.
    Helin-Salmivaara A; Korhonen MJ; Alanen T; Huupponen R
    J Clin Pharm Ther; 2012 Feb; 37(1):58-64. PubMed ID: 21410736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Coronary heart disease patient reaches LDL level of 100 mg/dl with atorvastatin: how do you continue treatment next year?].
    Weizel A; Sawicki PT
    MMW Fortschr Med; 2004 Dec; 146(51-52):14, 16. PubMed ID: 15675236
    [No Abstract]   [Full Text] [Related]  

  • 37. Exploring the Evolution of Statin Pricing in Australia: Observations of Price Disclosure Effects on Pharmaceutical Benefits Scheme Expenditure.
    Lee L; Kim H
    Value Health Reg Issues; 2024 Mar; 40():27-34. PubMed ID: 37972431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of statins.
    Huse DM; Russell MW; Miller JD; Kraemer DF; D'Agostino RB; Ellison RC; Hartz SC
    Am J Cardiol; 1998 Dec; 82(11):1357-63. PubMed ID: 9856919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Religious attendance: more cost-effective than lipitor?
    Denberg T
    J Am Board Fam Med; 2006; 19(4):430; author reply 431-3. PubMed ID: 16809663
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.